598
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Evaluating drugged driving: Effects of exemplar pain and anxiety medications

, , &
Pages S97-S103 | Received 01 Apr 2017, Accepted 07 Sep 2017, Published online: 27 Mar 2018

References

  • Basbaum AI, Fields HL. Endogenous pain control mechanisms: review and hypothesis. Ann Neurol. 1978;4:451–462.
  • Berning A, Compton R, Wochinger K. Results of the 2013–2014 National Roadside Survey of Alcohol and Drug Use by Drivers. Washington, DC: NHTSA; 2015.
  • Breivik H. Opioids in chronic non‐cancer pain, indications and controversies. Eur J Pain. 2005;9(2):127–130.
  • Brown T, Johnson R, Milavetz G. Identifying periods of drowsy driving using EEG. Ann Adv Automot Med. 2013;57:99.
  • Brown T, Lee J, Schwarz C, et al. Detection of driver impairment from drowsiness. Paper presented at: 23rd International Technical Conference on the Enhanced Safety of Vehicles; 2013; Seoul, South Korea.
  • Brown T, Milavetz G, Murry DJ. Alcohol, drugs and driving: implications for evaluating driver impairment. Ann Adv Automot Med. 2013;57:23.
  • Brown T, Spurgin A, Milavetz G, Gaffney G, Johnson R. Do drowsy driver drugs differ? Paper presented at: 8th International Driving Symposium on Human Factors in Driver Assessment, Training, and Vehicle Design; June 22–25, 2015; Park City, UT.
  • Buikhuis W, Jongman RW. Traffic perception under influence of alcohol. Q J Stud Alcohol. 1972;33:800.
  • Byas-Smith MG, Chapman SL, Reed B, Cotsonis G. The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain. 2005;21:345–352.
  • Carpenter JA. Effects of alcohol on some psychological processes: a critical review with special reference to automobile driving skill. Q J Stud Alcohol. 1962;23:274–314.
  • Center for Behavioral Health Statistics and Quality. 2015 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Office of Applied Studies, US Department of Health and Human Services; 2016.
  • Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592–596.
  • Compton RP, Berning A. Drug and Alcohol Crash Risk. Washington, DC: NHTSA; 2015. DOT HS 812 117.
  • Fishbain DA, Cutler RB, Rosomoff H, Rosomoff RS. Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother. 2002;16:9–28.
  • Gaffney G, Milavetz G, Brown T, Spurgin A, Johnson R. Peak versus off-peak effects of cannabis: impacts on driving performance. Paper presented at: NIDA International Forum; June 12–15, 2015; Phoenix AZ.
  • Governors Highway Safety Association. Drug Impaired Driving. 2016. Available at: http://ghsa.org/state-laws/issues/drug%20impaired%20driving. Accessed December 9, 2016.
  • Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology. 1973;10(4):431–436.
  • Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125:8–18.
  • Kaye AM, Kaye AD, Lofton EC. Basic concepts in opioid prescribing and current concepts of opioid-mediated effects on driving. Ochsner J. 2013;13:525–532.
  • Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77:295–301.
  • Lee J, Brown T, Fiorentino D, Fell J, Traube E, Nadler E. Using vehicle-based sensors of driver behavior to detect alcohol impairment. Paper presented at: 22nd International Technical Conference on the Enhanced Safety of Vehicles (ESV); June 13–16, 2011; Washington, DC.
  • Leufkens TR, Vermeeren A, Smink BE, Van Ruitenbeek P, Ramaekers JG. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. Psychopharmacology. 2007;191:951–959.
  • Mailis-Gagnon A, Lakha SF, Furlan A, Nicholson K, Yegneswaran B, Sabatowski R. Systematic review of the quality and generalizability of studies on the effects of opioids on driving and cognitive/psychomotor performance. Clin J Pain. 2012;28:542–555.
  • Maurer DC. Office of National Drug Control Policy: Progress toward Some National Drug Control Strategy Goals, but None Have Been Fully Achieved. Washington, DC: Testimony Before the Committee on Homeland Security and Governmental Affairs, U. S. Senate May 17, 2016. GAO (GAO-16-660T).
  • Mortimer RG, Sturgis SP. Alcohol and simulated car-following performance. In: Proceedings: American Association for Automotive Medicine Annual Conference, vol. 24. Association for the Advancement of Automotive Medicine; 1980:26–34.
  • Moskowitz H, Fiorentino D. A review of the scientific literature regarding the effects of alcohol on driving-related behavior at blood alcohol concentrations of 0.08 grams per deciliter and lower. Washington, DC: National Highway Traffic Safety Administration; 2000. (DOT HS 809 028).
  • National Center for Health Statistics. Health, United States, 2015: With Special Feature on Racial and Ethnic Health Disparities. Hyattsville, MD: Centers for Disease Control; 2016.
  • Office of Highway Policy Information. Our Nation's Highways 2011. Washington, DC: Federal Highway Administration; 2010. FHWA-PLL-11-028.
  • Ogden EJD, Moskowitz H. Effects of alcohol and other drugs on driver performance. Traffic Inj Prev. 2004;5:185–198.
  • Pickett C, Clum GA. Comparative treatment strategies and their interaction with locus of control in the reduction of postsurgical pain and anxiety. J Consult Clin Psychol. 1982;50:439.
  • Substance Abuse and Mental Health Services Administration. The DAWN Report: Benzodiazepines in Combination with Opioid Pain Relievers and Alcohol: Greater Risk for More Serious ED Visit Outcomes. Rockville, MD: US Department of Health and Human Services; 2014.
  • Turner JG, Clark AJ, Gauthier DK, Williams M. The effect of therapeutic touch on pain and anxiety in burn patients. J Adv Nurs. 1998;28:10–20.
  • Verster JC, Volkerts ER, Verbaten MN. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study. Neuropsychopharmacology. 2002;27:260–269.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.